After dominating the cystic fibrosis market for quite some time, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is currently expanding its clinical programs to
It’s worth keeping an eye on Vertex Pharma (VRTX) stock. Here’s why
Categories
Biotechnology
Will restructuring, cost-cutting help Walgreens (WBA) beat COVID blues?
The growing demand for new therapeutic solutions and advanced research in areas like human-genome will keep the biotechnology industry busy in the
Here’s what you need to know before investing in Amgen (AMGN)
The coronavirus outbreak has made leading pharma companies channelize their resources for vaccine development, and the efforts have been largely successful. While
With a Phase 2 success, Entera Bio’s pipeline might be worth betting on
Reporting by Arjun Vijay While rising interest in biotechnology has provided a much-needed fillip to the research and development of therapies, one
Entera Bio Ltd. (ENTX) Q4 2020 Earnings Call Transcript
Entera Bio Ltd. (NASDAQ: ENTX) Q4 2020 earnings call dated Mar. 18, 2021 Corporate Participants: Jonathan Lieber -- Chief Financial Officer, U.S.
Avid Bioservices, Inc. (CDMO) Q3 2021 Earnings Call Transcript
Avid Bioservices, Inc. (NASDAQ: CDMO) Q3 2021 earnings call dated Mar. 08, 2021 Corporate Participants: Tim Brons -- Investor Relations Nicholas Green -- President and Chief
Moderna (MRNA) to increase vaccine supply capacity and accelerate pipeline investments
Shares of Moderna Inc. (NASDAQ: MRNA) were up 6% in morning trade on Thursday after the company reported its fourth quarter and
Sage Therapeutics Inc. (SAGE) Q4 2020 Earnings Call Transcript
Sage Therapeutics Inc. (NASDAQ: SAGE) Q4 2020 earnings call dated Feb. 24, 2021 Corporate Participants: Jeff Boyle -- Vice President, Head of Investor Relations
Jazz Pharmaceuticals PLC (JAZZ) Q4 2020 Earnings Call Transcript
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q4 2020 earnings call dated Feb. 23, 2021 Corporate Participants: Andrea N. Flynn -- Vice President, Head of Investor
Solid pipeline makes ImmunoGen (IMGN) a good long-term investment
ImmunoGen Inc. (NASDAQ: IMGN) last week reported a profit after incurring losses in the first three quarters of last year. The surprise
ImmunoGen Inc. (IMGN) Q4 2020 Earnings Call Transcript
ImmunoGen Inc. (NASDAQ: IMGN) Q4 2020 earnings call dated Feb. 12, 2021 Corporate Participants: Courtney O'Konek -- Senior Director of Corporate Communications and Investor
Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ: CORT) Q4 2020 earnings call dated Feb. 08, 2021 Corporate Participants: Charles Robb -- Chief Financial Officer Joseph K. Belanoff -- Chief
Eylea recovery, COVID antibody cocktail make Regeneron an attractive bet
After last year's mixed performance, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) looks to take advantage of the robust pipeline and the success of
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2020 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Q4 2020 earnings call dated Feb. 05, 2021 Corporate Participants: Justin Holko — Vice President, Investor Relations Leonard S.
Bristol Myers (BMY) stock gains after Q4 results beat Street view
Bristol-Myers Squibb Company (NYSE: BMY) Thursday reported stronger-than-expected fourth-quarter results. The company's stock gained in the pre-market session soon after the announcement.
Biogen, Inc. (BIIB) Q4 2020 Earnings Call Transcript
Biogen, Inc. (NASDAQ: BIIB) Q4 2020 earnings call dated Feb. 03, 2021 Corporate Participants: Mike Hencke -- Director, Investor Relations Michel Vounatsos -- Chief Executive Officer
Infographic: Key financials of Biogen (BIIB) Q4 2020 earnings report
Biogen (NASDAQ: BIIB) reported fourth-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 22% decline in
Vertex Pharmaceuticals Inc (VRTX) Q4 2020 Earnings Call Transcript
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Q4 2020 earnings call dated Feb. 01, 2021 Corporate Participants: Michael Partridge -- Senior Vice President of Investor Relations
Novavax (NVAX) brings its share to the COVID-19 vaccine table; stock soars
Novavax Inc.’s (NASDAQ: NVAX) shares soared 50% in morning hours on Friday after the company announced that its COVID-19 vaccine candidate displayed
Fate Therapeutics (FATE) looks headed for a turnaround post-COVID
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market's attention after reporting positive results from advanced-stage clinical
Codexis (CDXS) may be moving closer to profitability, after beating slowdown
Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to